China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III clinical study in China for etripamil, a drug candidate being assessed as a treatment for paroxysmal supraventricular tachycardia (PSVT). The multi-center, randomized, double-blind, placebo-controlled Phase III study will evaluate the efficacy and safety of self-administered etripamil nasal spray for PSVT treatment, with over 40 hospitals in China participating.
Drug Profile
Etripamil was originally developed by Canada-based Milestone Pharmaceuticals Inc. (NASDAQ: MIST) and is a calcium channel blocker designed to act as a rapid-response therapy for episodic cardiovascular conditions. Milestone is conducting a comprehensive development program for etripamil, including ongoing Phase III trials in PSVT and a Phase II proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). In May 2021, Milestone and Jixing announced an exclusive license and collaboration agreement to develop and commercialize the investigational drug for PSVT and other cardiovascular conditions in Greater China. The green light to enter Phase I and III clinical studies in PSVT in China was received in November 2021.
Company Background
Backed by RTW Investments LP, Jixing was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics for unmet medical needs in cardiovascular and ophthalmic diseases. Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.-Fineline Info & Tech
